All In Biotech

Drug Trial Radar · NCT03900429

A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis

A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation

Last checked: Nov 20, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,759 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,759

Actual

Start

Mar 28, 2019

Primary completion

Jan 2028

Study completion Jan 2028

Sponsor

Lead sponsor
Madrigal Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Apr 3, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of MGL-3196 as compared with placebo resolves NASH and/or reduces fibrosis on liver biopsy and prevents progression to cirrhosis and/or advanced liver disease

Conditions

  • NASH - Nonalcoholic Steatohepatitis

Interventions

  • MGL-3196Drug

    Tablet

  • PlaceboDrug

    Matching Tablets

  • Liver BiopsyProcedure

    A procedure in which a needle is inserted into the liver to collect a tissue sample

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Week 52 Dual Primary Objectives: To determine the effect of 80 or 100 mg MGL-3196 vs matching placebo on liver biopsy (NASH CRN score) at Week 52 compared with BaselineTime frame: 52 weeks
  2. Month 54 Primary Objective: Time to experiencing an adjudicated Composite Clinical Outcome event (Final Primary Endpoint, at 54 months)Time frame: up to 54 months

Locations

247 sites in 16 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • East Valley Family Physicians

    Chandler, Arizona

  • The Institute for Liver Health - Chandler

    Chandler, Arizona

  • The Institute for Liver Health - Glendale

    Glendale, Arizona

  • Desert Clinical Research

    Mesa, Arizona

  • Adobe Gastroenterology

    Tucson, Arizona

  • The Institute for Liver Health - Tucson

    Tucson, Arizona

  • Arkansas Gastroenterology

    North Little Rock, Arkansas

  • Fresno Clinical Research Center

    Fresno, California

  • National Research Institute - Huntington Park

    Huntington Park, California

  • University of California San Diego

    La Jolla, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • National Research Institute - Los Angeles

    Los Angeles, California

  • Ruane Clinical Research

    Los Angeles, California

  • Stanford University School of Medicine

    Palo Alto, California

  • National Research Institute - Panorama City

    Panorama City, California

  • Alliance Clinical Research

    Poway, California

  • San Fernando Valley Health Institute

    Van Nuys, California

  • Colorado Springs Family Practice

    Colorado Springs, Colorado

  • South Denver Gastroenterology - Swedish Medical Center Office

    Englewood, Colorado

  • Excel Medical Clinical Trials

    Boca Raton, Florida

  • Covenant Metabolic Specialists - Fort Myers

    Fort Myers, Florida

  • University of Florida Hepatology Research at CTRB

    Gainesville, Florida

  • Nature Coast Clinical Research

    Inverness, Florida

  • Florida Research Institute

    Lakewood Rch, Florida

  • University of Miami

    Miami, Florida

  • Miami Dade Medical Research Institute

    Miami, Florida

  • Bioclinica Research - Orlando

    Orlando, Florida

  • Progressive Medical Research

    Port Orange, Florida

  • Covenant Research

    Sarasota, Florida

  • Bioclinica Research - The Villages

    The Villages, Florida

  • GI Specialists of Georgia

    Marietta, Georgia

  • Clinical Research - Chicago

    Chicago, Illinois

  • Northwestern Medical Faculty Foundation

    Chicago, Illinois

  • The University of Chicago Medicine

    Chicago, Illinois

  • University of Kansas Medical Center Research Institute

    Fairway, Kansas

  • Kansas Medical Clinic - Gastroenterology

    Topeka, Kansas

  • Texas Digestive Disease Consultants - Gastroenterology Associates - Baton Rouge

    Baton Rouge, Louisiana

  • Tandem Clinical Research

    Marrero, Louisiana

  • Tulane University School of Medicine

    New Orleans, Louisiana

Showing 40 of 247 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.